AIM ImmunoTech Inc.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $88.0K
- Net income
- -$14.0M
- Total assets
- $5.8M
- Market cap
- $7.5M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $7.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 2, 1995
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review AIM ImmunoTech Inc..